UNSPSC 51283712: Cefuroxime

This classification denotes a cephalosporin antibiotic, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O1R9FJ93ED. European Medicines Agency schedules Cefuroxime in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07433MIG. Cefuroxime generally arises in the molecular formula C16H16N4O8S.

UNSPSC 51283712 Cefuroxime is a Commodity code that encompasses pharmaceutical products procured by state and local health agencies, but recent state and local opportunities show no direct solicitations for cefuroxime itself. Instead, the code appears misaligned with actual procurement activity under this identifier. Recent opportunities tagged to this code involve naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, medical and first aid supplies for emergency response, and direct-to-manufacturer prescription program planning—none of which are cefuroxime-specific or antibiotic-focused. State and local buyers issuing under this code span county health departments (Seminole County, Florida), state HHS commissions (Texas), municipalities (City of Tampa), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). The issuing bodies reflect a mix of direct procurement and cooperative-purchasing vehicles designed to aggregate demand across jurisdictions.

Geographic activity centers on Florida, Texas, and Minnesota, with cooperative purchasing extending to Oregon and broader state and local participation. Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems with a July 26, 2023 response deadline; the City of Tampa's sealed-bid solicitation for medical and first aid supplies (169 line items for the Fire Department Rescue Division) due March 13, 2026, with an estimated contract value of $700,000 and SLBE set-aside designation; Minnesota's RFP for generic multi-source pharmaceuticals and OTC products through authorized wholesalers due March 26, 2026; and Texas HHS's RFI on direct-to-manufacturer prescription programs posted April 3, 2026. The code shows little relevant recent activity for cefuroxime procurement specifically, suggesting either a classification mismatch or dormant demand under this particular commodity identifier.